Texture Analysis of T2-Weighted Images as Reliable Biomarker of Chronic Kidney Disease Microstructural State
- PMID: 40564100
- PMCID: PMC12189524
- DOI: 10.3390/biomedicines13061381
Texture Analysis of T2-Weighted Images as Reliable Biomarker of Chronic Kidney Disease Microstructural State
Abstract
Objectives: The diagnostics of chronic kidney disease (CKD) consist of three basic groups of examinations: laboratory tests, radiological imaging and histopathological examinations. However, in the most severe clinical cases, where a fast, undisputed decision is required, histopathological tests are the only suitable option. Unfortunately, such tests require an invasive kidney biopsy, which is not possible in many patients. The aim of this study is to create an algorithm that can categorize CKD patients into active and non-active phases on the basis of MRI texture analysis and compare the results with histopathological examinations. Methods: MRI examinations were performed on healthy volunteers (group 1, N = 14) and CKD patients who also received kidney biopsy. The histopathological examination was used to divide the patients into active phase CKD (group 2, N = 58) and non-active phase CKD (group 3, N = 22). The T2-weighted MRI images were analyzed using a Support Vector Machine (SVM) model created with qMazDa software, which was trained to classify images into the appropriate group of CKD activity. Results: The following evaluation metrics were calculated for the final SVM models corresponding to confusion matrices: for texture analysis-balanced accuracy 81.6%, sensitivity 68.2-92.0%, specificity 82.5-97.5% and precision 62.5-95.8%; for texture and shape analysis-balanced accuracy 87.3%, sensitivity 77.3-100.0%, specificity 87.5-100.0% and precision 65.4-100.0%. Conclusions: Texture analysis of T2-weighted images associated with kidney shape features seems to be reliable method of assessing the state of ongoing CKD.
Keywords: CKD; MRI; T2-weighted images; chronic kidney disease; magnetic resonance; texture analysis.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures




Similar articles
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
-
Magnetic resonance perfusion for differentiating low-grade from high-grade gliomas at first presentation.Cochrane Database Syst Rev. 2018 Jan 22;1(1):CD011551. doi: 10.1002/14651858.CD011551.pub2. Cochrane Database Syst Rev. 2018. PMID: 29357120 Free PMC article.
-
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.Cochrane Database Syst Rev. 2011 Oct 5;(10):CD007751. doi: 10.1002/14651858.CD007751.pub2. Cochrane Database Syst Rev. 2011. Update in: Cochrane Database Syst Rev. 2023 Jul 19;7:CD007751. doi: 10.1002/14651858.CD007751.pub3. PMID: 21975774 Updated.
-
Intraoperative frozen section analysis for the diagnosis of early stage ovarian cancer in suspicious pelvic masses.Cochrane Database Syst Rev. 2016 Mar 1;3(3):CD010360. doi: 10.1002/14651858.CD010360.pub2. Cochrane Database Syst Rev. 2016. PMID: 26930463 Free PMC article.
-
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240. Health Technol Assess. 2006. PMID: 16796930
References
-
- Navaneethan S.D., Zoungas S., Caramori M.L., Chan J.C., Heerspink H.J., Hurst C., Liew A., Michos E.D., Olowu W.A., Sadusky T., et al. Diabetes Management in Chronic Kidney Disease: Synopsis of the KDIGO 2022 Clinical Practice Guideline Update. Ann. Intern. Med. 2023;176:381–387. doi: 10.7326/M22-2904. - DOI - PubMed
LinkOut - more resources
Full Text Sources